This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Cochrane Risk of Bias Tool | |
|---|---|
| Name | Cochrane Risk of Bias Tool |
| Developed | 2008 |
| Developer | Cochrane Collaboration |
| Purpose | Assess risk of bias in randomized trials |
Cochrane Risk of Bias Tool The Cochrane Risk of Bias Tool is a methodological instrument designed to assess internal validity of randomized controlled trials in systematic reviews. It informs interpretations of evidence by identifying potential biases across trial conduct and reporting, guiding reviewers from organizations such as World Health Organization, National Institutes of Health, Food and Drug Administration, European Medicines Agency and committees like US Preventive Services Task Force and National Institute for Health and Care Excellence.
The tool operationalizes bias domains to evaluate threats to trial validity used by reviewers at Cochrane Collaboration, members of the GRADE Working Group, staff of the British Medical Journal, analysts at the Agency for Healthcare Research and Quality, and guideline panels at bodies like World Health Organization. It contrasts with quality checklists developed by institutions such as CONSORT, PRISMA, and agencies including Centers for Disease Control and Prevention and National Institutes of Health. Major users include investigators at Johns Hopkins University, Harvard Medical School, University of Oxford, Stanford University, and public health groups like Médecins Sans Frontières.
The original instrument was published by researchers affiliated with Cochrane Collaboration and influenced by methodological work from scholars at Oxford University, McMaster University, University of Toronto, University College London, and the London School of Hygiene & Tropical Medicine. Subsequent updates incorporated input from panels including members of the GRADE Working Group and methodologists at Agency for Healthcare Research and Quality. Revisions paralleled reporting initiatives from CONSORT, editorial policies of The Lancet, New England Journal of Medicine, JAMA, and standards promoted by World Health Organization.
Domains evaluated by the instrument draw on concepts advanced by statisticians and trialists connected to Cochrane Collaboration, Cochrane Consumers and Communication Group, and academic centers such as Yale University, University of Cambridge, Columbia University, and King's College London. Core domains typically include sequence generation (with influences from researchers at University of Bristol), allocation concealment (discussed by analysts at Imperial College London), blinding (debated in publications in BMJ and The Lancet), incomplete outcome data (a focus at Mayo Clinic), selective reporting (highlighted by investigators at Harvard Medical School), and other biases (noted by reviewers at Cochrane Methods Group). Each domain uses signaling questions inspired by methodological frameworks from CONSORT and STROBE authors.
Review teams at institutions like Cochrane Collaboration, World Health Organization, National Institute for Health and Care Excellence, Agency for Healthcare Research and Quality, and academic groups at Johns Hopkins University apply the tool during data extraction and critical appraisal phases. The tool is used alongside search strategies developed with librarians from British Library, Library of Congress, and university libraries at University of California, Berkeley. Training materials produced by Cochrane Training and workshops at conferences such as International Congress on Peer Review and Scientific Publication and meetings of Society for Epidemiologic Research support implementation.
Assessments yield judgments commonly categorized as low, unclear, or high risk, an approach applied by guideline developers at National Institute for Health and Care Excellence, World Health Organization, and panels at U.S. Preventive Services Task Force. Presentation formats follow conventions promoted in journals like BMJ, JAMA, The Lancet, and New England Journal of Medicine using summary tables, traffic-light plots, and narrative synthesis. These outputs inform certainty ratings in GRADE evidence profiles and guideline recommendations by bodies such as World Health Organization and National Institute for Health and Care Excellence.
Empirical evaluations from research groups at University of Oxford, McMaster University, University of Bristol, Harvard Medical School, and Yale University have examined inter-rater reliability and construct validity. Critics in editorials at BMJ and The Lancet and scholars at Stanford University and Columbia University note limitations: subjectivity in judgments, variable inter-rater agreement, and challenges with poorly reported trials. Methodological debates reference contributions from the GRADE Working Group, regulatory science at Food and Drug Administration, and meta-researchers at Meta-Research Innovation Center at Stanford.
Extensions and related instruments developed by groups at Cochrane Collaboration, Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I), and authors affiliated with University of Oxford, McMaster University, GRADE Working Group, and Agency for Healthcare Research and Quality address nonrandomized studies and outcome-level assessments. Other allied tools and reporting standards include CONSORT, PRISMA, STROBE, and initiatives by journals such as BMJ, JAMA, and The Lancet aimed at improving trial conduct and transparency.
Category:Research methods